New Lifetime High Reached By Horizon Pharma (HZNP)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Horizon Pharma ( HZNP) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Horizon Pharma as such a stock due to the following factors:

  • HZNP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $89.2 million.
  • HZNP has traded 57,932 shares today.
  • HZNP is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in HZNP with the Ticky from Trade-Ideas. See the FREE profile for HZNP NOW at Trade-Ideas

More details on HZNP:

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. Currently there are 8 analysts that rate Horizon Pharma a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Horizon Pharma has been 4.1 million shares per day over the past 30 days. Horizon has a market cap of $5.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 2.26 and a short float of 10.6% with 4.79 days to cover. Shares are up 142.9% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher